The lab version is stronger and lasts longer than the natural one, which is why it has bigger effects but also more side effects
Antitumor activity of anlotinib in Malignant melanoma: modulation of angiogenesis and vasculogenic mimicry
Muchas personas tienen un lunar en el labio sin haberlo notado nunca
American Journal of Clinical Nutrition, 108(1), 13-22
Ipilimumab Evidence (ipilimumab): The open-label, three-arm, North American Intergroup trial E1609 (NCT01274338) compared two doses of ipilimumab with HDI as adjuvant therapy in high-risk patients with melanoma.[23] A total of 1,670 patients with resected disease (defined by the American Joint Committee on Cancer, 7th edition, as stage IIIB, IIIC, M1a, or M1b) were randomly assigned (1:1:1) to ipi3 or ipi10 every 3 weeks for four doses (induction), followed by the same dose every 12 weeks for four doses (maintenance), or HDI 20 million units/m2 per day, 5 days per week for 4 weeks (induction), followed by 10 million units/m2 daily subcutaneously every other day, 3 days per week for 48 weeks (maintenance).[23][Level of evidence A1] The trial was designed with two coprimary end points, RFS and OS, with a hierarchic analysis to evaluate ipi3 versus HDI followed by ipi10 versus HDI